Please try another search
InventisBio Co., Ltd., a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications. The company has a collaboration agreement with Betta Pharmaceuticals. InventisBio Co., Ltd. was founded in 2013 and is headquartered in Pudong, China.
Name | Age | Since | Title |
---|---|---|---|
Chen Wen | 56 | 2020 | Independent Director |
Dong Lu | 49 | 2020 | Director |
Yibin Shi | 35 | 2020 | Director |
Qinghua Feng | 37 | 2020 | Chairman of the Supervisory Board |
Jia Yan | 53 | 2020 | Independent Director |
Yaolin Wang | 61 | - | CEO & Chairman |
Xing Dai | 49 | - | Deputy GM & Director |
Yueheng Jiang | 53 | 2020 | Deputy GM, Secretary & Director |
Luwei Shi | 39 | 2015 | CFO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review